News Search Results
Aug 20, 2025, 08:37 ET Anixa Biosciences Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Chinese National Intellectual Property Administration (CNIPA)
More news about: Anixa Biosciences, Inc.
Aug 20, 2025, 08:00 ET Arthrosi Therapeutics Achieves Full Enrollment of the Second Pivotal Phase 3 Trial of Pozdeutinurad (AR882) in Patients with Gout, Including Those with Tophaceous Gout
DIEGO, Aug. 20, 2025 /PRNewswire/ -- Arthrosi Therapeutics, Inc., a late-stage biotechnology company advancing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares,
More news about: Arthrosi Therapeutics
Aug 20, 2025, 07:00 ET COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
million. The offering closed successfully in June. In June, CollPlant announced the expansion of its agreement with STEMCELL Technologies, a biotechnology company that develops and supplies specialized cell culture media, tools, and services to support research in stem cell biology, regenerative medicine,
More news about: CollPlant
Aug 19, 2025, 14:18 ET Kodiak Sciences to Present at American Chemical Society Fall 2025
Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present
More news about: Kodiak Sciences Inc.
Aug 19, 2025, 14:05 ET Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge
More news about: Myosin Therapeutics Inc.
Aug 19, 2025, 11:30 ET Convoke Raises $8.6M to Build the AI Operating System for Biopharma
Capital, Audacious, Lux Capital, and angels including Qasar Younis, Erik Torenberg, and other leaders in AI and biotechnology. The funding comes as biopharma companies are under pressure to reduce development cycle times and improve efficiency. New drugs spend ~45%
More news about: Convoke Holdings, Inc.
Aug 19, 2025, 11:15 ET Real World Evidence Solutions Market worth $10.83 billion by 2030 with 14.8% CAGR | MarketsandMarkets™
provider of technology solutions, advanced analytics, and clinical research services. The company's offerings play a crucial role in assisting biotechnology firms, medical device manufacturers, pharmaceutical companies, government agencies, medical researchers, payers, and healthcare stakeholders gain
More news about: MarketsandMarkets
Aug 19, 2025, 10:39 ET ADVANCION AWARDED ECOVADIS GOLD MEDAL FOR 2025 SUSTAINABILITY PERFORMANCE
supplier evaluation process. ABOUT ADVANCIONAdvancion is a leading global producer of specialty ingredients and consumables for biotechnology, pharmaceuticals, home, personal care, and other consumer-oriented and industrial markets. The Company is one of the world's largest producers of
More news about: Advancion Corporation
Aug 19, 2025, 10:01 ET 12.6% CAGR for Cancer Drugs Market to Reach US$516.15 billion by 2031, Due to Surging Investments in Oncology Research | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 19, 2025, 09:30 ET Lung Cancer Research Foundation Expands Scientific Advisory Board
PhDProject leader, Comprehensive Cancer Center, IRCCS San Raffaele Scientific InstituteAdjunct Assistant Professor/Lecturer, Biotechnology for Innovative Therapeutics, Medical School, Vita-Salute San Raffaele University, Milan, Italy
More news about: Lung Cancer Research Foundation
Aug 19, 2025, 08:30 ET Accelerating Data Entry for Non-GLP Pathology Studies, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 19, 2025, 08:00 ET Dominari Holdings Featured in The Wall Street Journal
Inc. (Nasdaq: DOMH) is pleased to share recent coverage in The Wall Street Journal highlighting the Company's successful transformation from its biotechnology origins into a growing, profitable financial services platform and investment bank.
More news about: Dominari Holdings Inc.
Aug 19, 2025, 06:00 ET Selonterra announces grant of United States patent on original discoveries in Alzheimer's disease
www.selonterra.com), a biotechnology company developing transformative therapies for neurodegenerative disorders announces that the U.S. Patent and Trademark Office (USPTO) has granted
More news about: Selonterra, Inc.
Aug 18, 2025, 17:00 ET Global X Announces Five ETF Reverse Stock Splits
1:5 Global X Genomics & Biotechnology ETF (GNOM) 37954Y434
More news about: Global X Management Company LLC
Aug 18, 2025, 17:00 ET REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS II
which has been shown to correlate with neurocognitive manifestations of the disorder. ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Aug 18, 2025, 12:48 ET Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President
More news about: Northwest Biotherapeutics
Aug 18, 2025, 12:37 ET Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman
Aug. 18, 2025 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB:NWBO) (the "Company" or "NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced with deep sadness the passing of its Senior Vice President
More news about: Northwest Biotherapeutics
Aug 18, 2025, 10:30 ET Beauty Devices Market Anticipated To Register 17.9% CAGR of During 2025-2031 by Increasing inclination toward beauty and wellness | The insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 18, 2025, 10:01 ET Hearing Aids Market Anticipated to Record US$ 45.68 billion by 2031 Due to Rising Geriatric Population | The Insight Partners
syndicated and consulting research services. We specialize in semiconductor and electronics, aerospace and defense, automotive and transportation, biotechnology, healthcare IT, manufacturing and construction, medical devices, technology, media and telecommunications, and chemicals and materials. Contact
More news about: The Insight Partners
Aug 18, 2025, 09:00 ET Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).
U.S. biotechnology company for its next-generation drug delivery platform, ACP (Advanced Cell Penetrating Peptide). Avixgen is a drug development company in which Dx&Vx holds a 66.2% stake. Through the licensing-out agreement, Avixgen grants the partner company, a U.S. biotechnology company,
More news about: Dx&Vx
Aug 18, 2025, 09:00 ET Anixa Biosciences Announces Treatment of Second Patient in Fourth Cohort of Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the second patient in the fourth dose cohort has been treated in
More news about: Anixa Biosciences, Inc.
Aug 18, 2025, 08:30 ET High-Titer Lentivirus Solutions in 5 Days: Break Production Barriers for CGT, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Reshoring Biologics Development and Manufacturing for a Streamlined Path to IND, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Unlocking Oncology Pipelines with Next-Gen AI and Functional Data, Upcoming Webinar Hosted by Xtalks
the global life science, food, healthcare and medical device communities. Every year, thousands of industry practitioners (from pharmaceutical, biotechnology, food, healthcare and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access
More news about: Xtalks
Aug 18, 2025, 08:30 ET Klotho Neurosciences Provides Shareholder Update Highlighting Recent Milestones as It Prepares to Address $8 Billion Neurodegenerative Disease Market
Aug. 18, 2025 /PRNewswire/ -- Klotho Neurosciences, Inc. (NASDAQ: KLTO) ("Klotho" or "the Company"), a biotechnology company advancing Klotho-based therapeutics for neurodegenerative diseases, provides a strategic update to shareholders highlighting the Company's
More news about: Klotho Neurosciences, Inc.